UPDATE: SVB Leerlink On FibroGen Price Target Trim: Given Failures Of Clinical Development And Lack Of Disclosure With Analytical And Regulatory Operations, Firm Believes It Is 'Appropriate' To Maintain A Low Probability Of Success